RNS Number:6299M
Protherics PLC
23 June 2003





                                                                    23 June 2003


                                 Protherics plc

                            Appointment of Directors



Following the offer to acquire the whole of the issued and to be issued share
capital of Enact Pharma plc ("Enact") being declared unconditional in all
respects, Protherics plc ("Protherics"), announces the following appointments to
the board with effect from 20 June 2003:

   *Dr Tony Atkinson as Chief Scientific Officer; and

   *Dr Mike Peagram as a non-executive director

Dr Atkinson (age 58) has extensive experience within the biopharmaceutical
industry having previously served as a director of Enact Pharma plc, Kymed G B
Limited and Enzacta R&D Limited.

Dr Peagram (age 60) previously served as Chairman of Enact Pharma plc. He is
Deputy Chairman of Yule Catto and Co plc and was previously a Director of CRC
Group plc and brings a wide range of business experience.

Further to disclosure requirements of the UK Listing Authority, as specified in
the Listing Rules, there are no further points under Rule 16.4(a) or 16.4(b)
which require disclosure.

Commenting on the appointment, Stuart Wallis, Chairman of Protherics, said:

"We are delighted to welcome Tony and Mike to the Board of Protherics. Tony's
extensive industry experience will help to guide our research and development
programme, while Mike will add further strength to the Board in a non-executive
capacity."



                                    - ENDS -




For Further Information Please Contact:



Protherics plc                 Tel: +44 (0) 20 7246 9950

Andrew Heath, CEO

Maitland Consultancy           Tel: +44 (0) 20 7379 5151

Brian Hudspith

Notes to editors:

Protherics PLC

Protherics PLC was formed in September 1999 from the merger of Proteus
International plc and Therapeutic Antibodies Inc. Protherics is an international
biopharmaceutical company, whose platform technology is the development and
production of immunotherapeutics.

The Company's ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange.

An electronic version of this will be available at: www.protherics.com










                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOANKNKDKBKDAAB